Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma

Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All news from this category: Technology Offerings

Back to the Homepage

Comments (0)

Write comment

Latest posts

Novel chirped pulses defy ‘conventional wisdom’

University of Rochester researchers describe first highly chirped pulses created by a using a spectral filter in a Kerr resonator. The 2018 Nobel Prize in Physics was shared by researchers…

Scientists design superfast molecular motor

Light-driven molecular motors have been around for over twenty years. These motors typically take microseconds to nanoseconds for one revolution. Thomas Jansen, associate professor of physics at the University of…

Changing a 2D material’s symmetry can unlock its promise

Jian Shi Research Group engineers material into promising optoelectronic. Optoelectronic materials that are capable of converting the energy of light into electricity, and electricity into light, have promising applications as…

Partners & Sponsors